



Potential Utility of Systemic Immune-Inflammation Index: NLR, PLR, and SII to Detect Poor Prognosis of COVID-19 Patients from the Mexican Southeast

Guadalupe del Carmen Baeza-Flores ¹, Juan Eduardo Gomez-Aguilar ¹, Merari Ruiz-Gomez ¹, Erika Ruby Correa-Espino ¹, Edgar David Hernandez-Lendechey ¹, Xavier Miguel Boldo-Leon ¹, Juan Pedro Luna-Arias ², Jesus A Ruiz-Quinones ³, Jesus M Magana-Cerino ^{1,3}, Mirian Carolina Martinez-Lopez ^{1,*}

¹ Molecular Diagnostic Laboratory, Research Center, Academic División of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa, Mexico

² Center for Research and Advances Studies of the National Polytechnic Institute (CINVESTAV-IPN), CDMX, Mexico

³ Research Center for Tropical and Emerging Diseases, High Specialty Regional Hospital "Dr. Juan Graham Casasús", 86126, Villahermosa, Mexico

*Corresponding Author: Molecular Diagnostic Laboratory, Research Center, Academic División of Health Sciences (DACS), Juarez Autonomous University of Tabasco (UJAT), Villahermosa, Mexico. Email: martinezlopez@hotmail.com

Received: 11 January, 2024; Revised: 14 December, 2024; Accepted: 29 December, 2024

Abstract

Background: Since December 2019, the SARS-CoV-2 virus has been highly contagious and pathogenic, causing mild to severe respiratory failure. The most investigated biomarkers can help to predict disease progression and guide treatment decisions. Expert clinicians suggested that the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) represent rapid, easy, widely available, and relatively inexpensive tools.

Objectives: We aimed to explore the NLR and PLR in predicting the poor prognosis of COVID-19 patients in the Mexican Southeast.

Methods: In this retrospective study, we included hospitalized adults with COVID-19 from Dr. Juan Graham Casasús Hospital who had survived or non-survived between June 2020 and January 2022. Demographic and laboratory data were acquired from electronic medical records. We calculated NLR, PLR, and SII. The continuous variables were expressed as average and were compared with the Student *t*-test, as well as with the categorical variables. These were expressed as numbers and percentages and were compared with the χ^2 test between the survivor group and the non-survivor group. The sensitivity and specificity in the prediction of death according to the cutoff values of the NLR, PLR, and the SII by ROC curve. *P* values less than 0.05 were considered significant.

Results: We admitted 189 patients. The average age was 61.8 ± 17.3 years, 59.8% ($n = 113$) were men, and 55.6% ($n = 105$) were non-survivors. We showed differences among survivors and non-survivors, age (65.6 vs. 56.9 $P = 0.001$), white blood cell count (14.1 vs. 10.2 $P = 0.001$), neutrophil (12.4 vs. 8.5 $P = 0.002$), CRP (213.7 vs. 158.5 $P = 0.003$), IL-6 (192.3 vs. 81.0 $P = 0.005$), NLR (23.5 vs. 11.4 $P = 0.000$), PLR (524.8 vs. 287.6 $P = 0.010$), SII (6982.0 vs. 3003.1 $P = 0.004$). The optimal cutoff for the NLR was 8.6 with a sensitivity of 70.4% and a specificity of 51.8 (AUC 0.678, CI 95% 0.6024 - 0.7541, $P < 0.0001$), for the PLR where it shows 252.6 with a sensitivity of a 60.0% and a specificity of 50.6 (AUC 0.6096, CI 95% 0.5297 - 0.6895, $P < 0.0099$), for the SII that 1815 with a sensitivity of 70.4%, and a specificity of 51.8 (AUC 0.6566, CI 95% 0.5788 - 0.7344, $P < 0.0002$).

Conclusions: We propose that NLR, PLR, and SII should be considered an inexpensive, accessible, and effective biomarker in the management of patients with COVID-19. In conclusion, the high NLR, PLR, and SII were related to poor prognosis in COVID-19 patients.

Keywords: Neutrophil-lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR), COVID-19, Prognosis, Biomarker

1. Background

In 2019, the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) virus was highly contagious and pathogenic, causing mild to severe respiratory failure (1). The emergence of COVID-19 for some authors represents a health public catastrophe due to the high infection rate and the risk of multiple organ involvement or death (2). The clinical spectrum of infection was wide. The most common symptoms at the

COVID-19 onset were fever, cough, myalgia, fatigue, sputum production, headache, diarrhea, and dyspnea (3).

To understand the mechanism involved in COVID-19 pathogenesis, Rasool and coworkers separated routine laboratory testing into two groups. The first group evaluated the proinflammatory response consistent with cytokine storm, and the second group evaluated the progression to multi-organ damage/failure (hepatic,

cardiac, renal) (4). The most investigated biomarkers could help to predict disease progression and guide treatment decisions (5-7).

In this sense, the biomarkers as lactate dehydrogenase (LDH), aspartate transaminase (AST), C-reactive protein (CRP), ferritin, D-dimer, IL-2R, IL-2, IL-10 and TNF α [2] (8, 9), white blood cell count, are measures of anticoagulation, and procalcitonin (10) to the monitoring of patients during COVID-19 infection.

The COVID-19 infection dramatically increased hospitalization costs. There are current studies suggesting that high rates of hospitalization, medications, diagnosis, and follow-up (laboratory tests and medical imaging) were the factors that increased the costs of management during the pandemic (11, 12). However, it has been reported that new prognostic parameters can help quickly and cheaply identify patients at risk for severe SARS-CoV-2 infection quickly and cheaply (13). Concerning these issues, the routine blood count is cheap and extremely important in predicting the prognosis of severe COVID-19 patients (14). Although some researchers and expert clinicians suggested that systemic immune-inflammatory biomarkers highlighted the potential role of the neutrophil-lymphocyte ratio (NLR), and the platelet-lymphocyte ratio (PLR) represented a rapid, easy, widely available, and relatively inexpensive tool (15, 16) that can serve as a valuable predictor of hospital mortality and has been proposed as a new biomarker for systemic inflammation (17, 18).

Unfortunately, many patients were hospitalized with COVID-19 pneumonia in Mexico, and we faced higher costs for management.

2. Objectives

Hence, the primary objective of our study was to calculate the NLR and the PLR and determine the relation to the prognosis of COVID-19 patients in the Mexican Southeast.

3. Methods

Following ethics criteria, this study was recorded in the Australian New Zealand Clinical Trial Register (ACTRN12620001265965) and the ethics committee of Dr. Juan Graham Casasús Hospital (CEIJGC-2023-04). This retrospective study included 189 records from patients admitted to Dr. Juan Graham Casasús Hospital at

Villahermosa, Tabasco, México, SARS-CoV-2 infection confirmed by PCR between June 2020 and January 2022. As it was of a retrospective nature, the informed consent was waived.

3.1. Data Collection

We extracted epidemiological, clinical, and laboratory data from electronic medical records. The epidemiological variables included age and sex. The clinical variables included comorbid conditions, symptoms at admission, number of hospital days, and discharge status. Finally, we examined the clinical laboratory variables: Complete blood count, blood chemistry analyses, coagulation test, levels of ferritin, Dimer-D, CRP, LDH, and interleukin-6 (IL-6).

We calculated the Systemic Immune-Inflammation Index following formulas: Neutrophil Lymphocyte Ratio: Absolute neutrophil count/the absolute lymphocyte count, PLR: Absolute platelet count/absolute lymphocyte count, Systemic inflammatory Index (SII): (Absolute platelet count) (absolute neutrophil count)/absolute lymphocyte count.

3.2. Statistical Analysis

Statistical analyses were performed using the SPSS software (version 25). Participants' epidemiological, clinical, and laboratory data were summarized with descriptive statistics. The continuous variables were expressed as average and compared with the Student *t*-test, and categorical variables were expressed as numbers and percentages. These were compared with the χ^2 test, which was a test between the survivor group and the non-survivor group. P-values less than 0.05 were considered significant.

The sensitivity and specificity in the prediction of death, according to the cutoff values of the NLR, PLR, and SII, were determined by the ROC curve. Then, the patient's data were divided into two groups according to the cutoff value (lower than the cutoff and higher than the cutoff).

4. Results

We admitted 189 patients with confirmed SARS-CoV-2 who were hospitalized at the Dr. Juan Graham Casasús Hospital. The average age was 61.82 ± 17.3 years. Most of the included patients were men, 59.8% ($n = 113$). The main symptom was cough; hypertension was the most

Table 1. Patient Features on Hospital Admission ^a

Features	Values
Age	61.82 ± 17.3
Male (n = 113)	59.8
Symptoms	
Fever (n = 123)	65.1
Cough (n = 147)	77.8
Sore throat (n = 48)	25.4
Dyspnea (n = 128)	67.7
Chest pain (n = 54)	28.6
Headache (n = 129)	68.3
Myalgias (n = 79)	41.8
Arthralgias (n = 76)	40.2
Runny nose (n = 38)	20.1
Comorbidities	
Diabetes (n = 61)	32.3
Hypertension (n = 76)	40.2
CKD (n = 14)	7.4
Obesity (n = 42)	22.2
Death (n = 105)	55.6
Hospital stay (d)	11.7 ± 11.2

Abbreviation: CKD, chronic kidney disease.

^a Values are expressed as % or mean ± SD.

common comorbidity. The frequency of death was 55.6% (n = 105). The rest of the features are listed in [Table 1](#).

The laboratory results were obtained at hospital admission, and comparisons between survivors and non-survivors are presented in [Table 2](#). The comparison of survivors and non-survivors showed a significant difference among age (65.6 vs. 56.9 P = 0.001), white blood cell count (14.1 vs. 10.2 P = 0.001), neutrophil (12.4 vs. 8.5 P = 0.002), CRP (213.7 vs. 158.5 P = 0.003), IL-6 (192.3 vs. 81.0 P = 0.005), NLR (23.5 vs. 11.4 P = 0.000), PLR (524.8 vs. 287.6 P = 0.010), SII (6982.0 vs 3003.1 P = 0.004).

[Figure 1](#) shows that the optimal cutoff for the NLR was of 8.6 with a sensitivity of 70.4% and a specificity of 51.8% (AUC 0.678, CI 95% 0.6024 - 0.7541, P < 0.0001), the optimal cutoff for the PLR was of 252.6 with a sensitivity of 60.0% and a specificity of 50.6% (AUC 0.6096, CI 95% 0.5297 - 0.6895, P < 0.0099), and the optimal cutoff for the SII was of 1815 with a sensitivity of 70.4% and a specificity of 51.8% (AUC 0.6566, CI 95% 0.5788 - 0.7344, P < 0.0002).

Among all the cases studied, the 60.3% (n = 114) had NLR > 8.6. [Table 3](#) shows the comparison of the NLR < 8.6 and > 8.6. There was a significant difference in age (58.2 ± 17.1 vs. 64.1 ± 16.6 P = 0.021), hospital stay (99.6 ± 9.6 vs.

13.1 ± 11.9 P = 0.033), gender (male 37 vs. 76 P = 0.017), white blood cell count (9.0 ± 10.4 vs. 14.5 ± 5.5 P < 0.000), CRP (136.7 ± 84.9 vs. 224.7 ± 126.3 P < 0.000), urea (48.1 ± 33.3 vs. 69.6 ± 60.0 P = 0.005), BUN (22.1 ± 15.4 vs. 32.6 ± 28.0 P = 0.003), LDH (411.2 ± 237.9 vs., 529.5 ± 413.9 P = 0.0029), fibrinogen (456.7 ± 161.4 vs. 634.3 ± 212.6 P = 0.000), IL-6 (91.3 ± 166.9 vs. 180.7 ± 256.4 P = 0.025) and death (31 vs. 74 P = 0.002).

A total of 55.0% (n = 104) had PLR > 252.6. Appendices 1 and 2 in Supplementary File show the comparison of PLR < 252.6 and > 252.6. There was a significant difference among hospital stay (9.5 ± 9.8 vs. 13.5 ± 11.9 P = 0.012), gender (male 44 vs. 69 P = 0.042), white blood cell count (10.9 ± 10.3 vs. 13.5 ± 5.9 p = 0.030), lymphocyte count (3.1 ± 9.8 vs. 0.6 ± 0.3 P = 0.010), neutrophil (8.6 ± 10.8 vs. 12.3 ± 5.8 P = 0.003), platelet count (176.7 ± 85.5 vs. 302.4 ± 203.1 P = 0.000), CRP (163.0 ± 114.9 vs. 211.1 ± 119.3 P = 0.010), fibrinogen (458.9 ± 178.3 vs. 651.2 ± 198.5 P = 0.000), NLR (7.3 ± 6.6 vs 27.0 ± 22.7 P = 0.000) and SII (1271.0 ± 1186.3 vs 8408.9 ± 11617.8 P = 0.000).

We also examined the comparison of SII < 1815, and > 1815, 60.3% (n = 114) had SII > 1815, there was a significant difference among age (57.3 ± 17.2 vs. 64.7 ± 16.3 P = 0.004), hospital stay (9.3 ± 10.1 vs. 13.3 ± 11.6 P = 0.018), gender

Table 2. Laboratory Features on Hospital Admission and Comparison Between Survivors and Non-survivors ^a

Variables	Values	Discharge		P-Value
		Non-survivors	Survivors	
Age (y)	61.82 ± 17.3	65.6 ± 16.2	56.9 ± 16.9	0.001 ^b
Gender (%)				0.457
Male (n = 113)	59.8	64	49	
Female (n = 76)	40.2	41	34	
Red blood cell count (10 ⁶ /μL)	4.2 ± 0.9	4.1 ± 1.0	4.3 ± 0.8	0.115
Hemoglobin (g/dL)	12.4 ± 2.7	12.2 ± 2.9	12.8 ± 2.3	0.138
Hematocrit (%)	37.7 ± 8.0	37.1 ± 8.7	38.6 ± 6.7	0.223
White blood cell count (10 ³ /μL)	12.3 ± 8.3	14.1 ± 9.6	10.2 ± 5.4	0.001 ^b
Lymphocyte count (10 ³ /μL)	1.7 ± 6.7	2.0 ± 8.6	1.3 ± 2.9	0.501
Neutrophil (10 ³ /μL)	10.6 ± 8.6	12.4 ± 10.2	8.5 ± 5.4	0.002 ^b
Platelet count (10 ³ /μL)	245.9 ± 172.6	255.8 ± 204.8	234.8 ± 121.4	0.409
CRP (mg/L)	189.4 ± 119.4	213.7 ± 122.2	158.5 ± 109.6	0.003 ^b
Glucose (mg/dL)	177.7 ± 101.3	180.3 ± 106.1	175.4 ± 95.5	0.743
Urea (mg/dL)	61.1 ± 52.1	67.5 ± 53.9	53.4 ± 49.1	0.067
BUN	28.5 ± 24.4	31.4 ± 25.8	24.9 ± 22.9	0.072
Creatinine (mg/dL)	2.0 ± 5.5	2.4 ± 7.1	1.5 ± 2.6	0.293
ALT (U/L)	50.8 ± 69.4	47.8 ± 78.3	55.2 ± 56.4	0.483
AST (U/L)	73.8 ± 150.1	82.6 ± 195.7	62.5 ± 48.6	0.378
Alkaline phosphatase (U/L)	125.9 ± 91.6	126.6 ± 86.8	122.4 ± 95.7	0.764
LDH (U/L)	480.7 ± 356.1	578.6 ± 434.8	548.8 ± 181.9	0.000 ^b
Fibrinogen	563.3 ± 211.9	580.6 ± 227.7	548.8 ± 181.9	0.384
D-dimer (mg/L)	4.6 ± 13.3	6.6 ± 15.5	2.1 ± 9.4	0.033 ^b
Prothrombin time (s)	13.2 ± 3.9	13.8 ± 5.0	12.4 ± 1.1	0.022 ^b
aPTT (s)	34.3 ± 15.7	34.1 ± 12.5	34.1 ± 18.9	0.993
Serum ferritin (ng/mL)	743.0 ± 933.4	851.9 ± 1099.3	603.2 ± 654.3	0.103
Procalcitonin (ug/L)	1.4 ± 5.1	2.0 ± 6.4	0.6 ± 2.3	0.090
IL-6 (pg/mL)	145.2 ± 228.7	192.3 ± 258.7	81.0 ± 160.5	0.005 ^b
NLR	18.1 ± 20.0	23.5 ± 24.1	11.4 ± 9.7	0.000 ^b
PLR	418.3 ± 626.4	524.8 ± 809.2	287.6 ± 190.1	0.010 ^b
SII	5198.7 ± 9340.9	6982.0 ± 11877.8	3003.1 ± 377.8	0.004 ^b

Abbreviations: CRP, C Reactive Protein; BUN, Blood Urea Nitrogen; ALT, Alanine transaminase; AST, Aspartate transaminase; aPTT, activated partial thromboplastin time; LDH, Lactate dehydrogenase; NLR, Neutrophil-Lymphocyte Ratio; PLR, Platelet Lymphocyte Ratio; SII, Systemic Inflammatory Index.

^a Values are expressed as mean ± SD unless otherwise indicated.

^b P < 0.05.

(male 37 vs. 76 P = 0.017), white blood cell count (8.7 ± 10.4 vs. 14.7 ± 5.3 P = 0.000), lymphocyte count (3.3 ± 10.5 vs. 0.7 ± 0.4 P = 0.009), neutrophil (5.4 ± 3.5 vs. 14.1 ± 9.2 P = 0.000), platelet count (168.3 ± 83.3 vs. 297.0 ± 196.0 P = 0.000), CRP (145.2 ± 101.0 vs. 218.3 ± 122.1 P = 0.000), urea (50.5 ± 40.9 vs. 68.0 ± 57.4 P = 0.024), BUN (23.2 ± 19.0 vs. 31.9 ± 26.8 P = 0.017), fibrinogen (451.4 ± 176.9 vs. 635.7 ± 201.8 P = 0.000), IL6 (87.3 ± 170.9 vs. 183.3 ± 253.7 P = 0.016) NLR (5.3 ± 4.7 vs. 26.5 ± 21.7 P = 0.000) and PLR (155.5 ± 87.1

vs. 591.3 ± 756.2 P = 0.000) and death (31 vs. 74 P = 0.002) (Appendix 2 in Supplementary File).

5. Discussion

We aimed to understand the role of NLR in the prognosis of COVID-19 patients in the Mexican Southeast. Here, it was highlighted that age, white blood cell count, neutrophil, CRP, LDH, d-dimer, prothrombin




Figure 1. ROC curve for the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and SII

time, IL-6, NLR, PLR, and SII differed between survivors and non-survivors.

In general, the results show that the age, white blood cell count, neutrophil, CRP, IL-6, NLR, PLR, and SII were significantly higher in the non-survivor group. In agreement with the previous reports of age, IL-6, and the CRP, there was a strong association with respiratory failure (19). Likewise, leukocytosis and lymphopenia, high levels of ALT, LDH, D-dimer and ferritin, IL-2R, IL-8, IL-10, and TNF- α were more common in severe cases (2, 6, 20).

In hospitalized patients with COVID-19 in Southeast Mexico, we have found that higher NLR shows significant differences within older age, hospital stay, gender, white blood cell count, CRP, urea, BUN, LDH, fibrinogen, IL-6, and death. We emphasized similarities with a report performed on the Chinese population, where 245 admitted patients, and found that the NLR

was higher. This was significantly associated with an increased risk of death during hospitalization (17).

There are currently some published studies with different levels of evidence about the role of NLR in the prognosis of patients with COVID-19 (14, 20, 21). As noted in a recent review, NLR may improve its usefulness to clinicians in assessing the patient's condition and the severity of inflammation in the course of COVID-19. It was suggested that higher NLR is related to patients who died (22). Now, it is recognized that the elevated NLR was an independent prognostic biomarker that concerned pneumonia progression in COVID-19 patients (23, 24).

Studies have reported that NLR showed high sensitivity and specificity for prognosis of COVID-19 (25, 26). In this study, we also found that NLR showed a sensitivity of 70.4% and a specificity of 51.8% (AUC 0.678, IC 0.6024 - 0.7541, $P < 0.0001$) at a cutoff of 8.6. This

Table 3. Laboratory Features on Hospital Admission and Comparison Between Neutrophil-Lymphocyte Ratio Cutoff ^a

Variables	NLR		P-Value
	< 8.6	> 8.6	
Age (y)	58.2 ± 17.1	64.1 ± 16.6	0.021 ^b
Hospital stay (d)	9.6 ± 9.6	13.1 ± 11.9	0.033 ^b
Male	37 (49.3)	76 (66.7)	0.017 ^b
Red blood cell count (10 ⁶ /μL)	4.2 ± 0.9	4.2 ± 0.8	0.715
Hemoglobin (g/dL)	12.5 ± 2.7	12.4 ± 2.6	0.725
Hematocrit (%)	38.0 ± 8.0	37.5 ± 8.0	0.686
White blood cell count (10 ³ /μL)	9.0 ± 10.4	14.5 ± 5.5	0.000 ^b
Lymphocyte count (10 ³ /μL)	3.3 ± 10.5	0.6 ± 0.3	0.006 ^b
Neutrophil (10 ³ /μL)	5.6 ± 3.7	14.0 ± 9.3	0.000 ^b
Platelet count (10 ³ /μL)	193.5 ± 106.4	280.3 ± 197.9	0.001 ^b
CRP (mg/L)	136.7 ± 84.9	224.7 ± 126.3	0.000 ^b
Glucose (mg/dL)	172.5 ± 106.6	181.1 ± 98.1	0.571
Urea (mg/dL)	48.1 ± 33.3	69.6 ± 60.0	0.005 ^b
BUN	22.1 ± 15.4	32.6 ± 28.0	0.003 ^b
Creatinine (mg/dL)	1.4 ± 1.9	2.4 ± 6.9	0.215
ALT (U/L)	47.7 ± 43.7	52.8 ± 82.9	0.647
AST (U/L)	75.9 ± 111.9	72.3 ± 172.3	0.877
Alkaline phosphatase (U/L)	125.7 ± 87.9	126.1 ± 94.6	0.974
LDH (U/L)	411.2 ± 237.9	529.5 ± 413.9	0.029 ^b
Fibrinogen	456.7 ± 161.4	634.3 ± 212.6	0.000 ^b
D-Dimer (mg/L)	3.7 ± 11.7	5.2 ± 14.2	0.465
Prothrombin time (s)	12.9 ± 2.3	13.5 ± 4.7	0.340
aPTT (s)	34.4 ± 11.1	34.2 ± 18.3	0.930
Serum ferritin (ng/mL)	626.7 ± 629.2	817.2 ± 1080.7	0.218
Procalcitonin (ug/L)	0.69 ± 1.8	1.8 ± 6.4	0.0149
IL-6 (pg/mL)	91.3 ± 166.9	180.7 ± 256.4	0.025 ^b
PLR	162.6 ± 90.1	586.6 ± 758.6	0.000 ^b
SII	921.7 ± 718.5	921.7 ± 11166.7	0.000 ^b
Death (N = 105)	31 (41.9)	74 (64.9)	0.002 ^b

Abbreviations: CRP, C reactive protein; BUN, blood urea nitrogen; ALT, alanine transaminase; AST, aspartate transaminase; aPTT, activated partial thromboplastin time; LDH, lactate dehydrogenase; NLR, neutrophil-lymphocyte ratio; PLR, platelet lymphocyte ratio; SII, systemic Inflammatory Index.

^a Values are expressed as mean ± SD or No. (%).

^b P < 0.05.

demonstrates a potential utility in detecting differences among cases in our population. Another study had already demonstrated that the ideal cutoff values for NLR were 8.4 with 83.6% specificity and 80.4% sensitivity (26). So far, there are different reports concerning the cutoff of NLR. In patients from Cairo, it was reported that there was a 52.7% sensitivity and an 82.9% specificity at a cutoff of 2.5 (25). In other research, the threshold was at 3.3 for NLR; It showed a superior prognostic possibility of clinical symptoms, which were changing

from mild to severe (24). More specifically, the optimal cutoff for NLR was 5.2, which was an independent predictor of the requirement for admission to a critical care unit (20).

The findings from this analysis also suggest that PLR and SII would help to identify prognosis and risk of death (22, 27, 28). In this study, we also found that the PLR > 252.6 and SII > 1815 showed significant differences in markers related to diagnosis, severity, or mortality in COVID-19 patients.

In other pathologies, a higher NLR value at hospital admission was associated with mortality in solid cancer patients (29-31) with Hodgkin lymphoma (32), in acute ischemic stroke patients who were receiving reperfusion therapy. The NLR predicted clinical outcomes (33). Also, prior studies have defined elevated NLR as associated with an increased risk of developing persistent organ failure in patients with hypertriglyceridemic pancreatitis (34). Regarding the available literature, NLR and SII exhibit capabilities for postoperative pneumonia in elderly hip fracture patients (35). Likewise, the inflammatory biomarkers NLR, PLR, and SII have been suggested as a potential prognostic tool for depression and its severity (36), diabetic microvascular complications (37), and predicting severe forms of acute cholecystitis (38).

Our study has some notable limitations. Firstly, this study was retrospective in nature and cross-sectional design. Secondly, the data extraction was in a single center, the Dr. Juan Graham Casasús Hospital. Thirdly, our study included 189 patients for evaluation of the new systemic inflammation markers from results found at hospital admission but did not include the dynamic during the hospital stay.

In conclusion, we propose that NLR, PLR, and SII should be considered an inexpensive, accessible, and effective biomarker in the management of patients with COVID-19. The age, hospital stay, gender, white blood cell count, CRP, urea, BUN, LDH, fibrinogen, IL-6, and death had significant differences with elevated inflammatory indexes. Finally, the high NLR, PLR, and SII were related to poor prognosis in COVID-19 patients.

Supplementary Material

Supplementary material(s) is available [here](#) [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Footnotes

Authors' Contribution: Study concept and design: M. C. M-L. and G. del C. B. F.; Acquisition of data: G. del C. B. F., J. E. G-A., E. C-E., M. R-G., and E. D. H-L.; Analysis and interpretation of data: G. del C. B. F., J. E. G-A., E. C-E, M. R-G, and E. D. H-L.; Drafting of the manuscript: G. del C. B. F. and J. E. G-A.; Critical revision of the manuscript for important intellectual content: J. P. L. A. and X. M. B. L.;

Statistical analysis: G. del C. B. F. and J. A. R. Q.; Administrative, technical, and material support: J. M. M. C., J. P. L. A., J. A. R. Q., and M. C. M-L.; Study supervision: J. M. M. C., J. P. L. A., J. A. R. Q., and M. C. M. L.

Clinical Trial Registration Code: ACTRN12620001265965.

Conflict of Interests Statement: The authors declared no conflict of interests.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication. The data are not publicly available due to privacy.

Ethical Approval: This study is approved under the ethical approval code of CEIJGC-2023-04.

Funding/Support: This work was partially supported by CONACYT grant No. 314119 (Implementación del laboratorio de diagnóstico molecular y vigilancia epidemiológica del Hospital COVID-19- Juan Graham Casasús de Villahermosa, Tabasco), as well as internal funding from Dr. Juan Pedro's laboratory (CINVESTAV-IPN) and the Molecular Diagnostic laboratory of DACS-UJAT and CIETE from Juan Graham Hospital.

References

1. Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. *Biochimie*. 2020;**179**:85-100. [PubMed ID: [32971147](#)]. [PubMed Central ID: [PMC7505773](#)]. <https://doi.org/10.1016/j.biochi.2020.09.018>.
2. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. 2020;**130**(5):2620-9. [PubMed ID: [32217835](#)]. [PubMed Central ID: [PMC7190990](#)]. <https://doi.org/10.1172/JCI137244>.
3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;**395**(10223):497-506. [PubMed ID: [3198264](#)]. [PubMed Central ID: [PMC7159299](#)]. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
4. Rasool G, Riaz M, Abbas M, Fatima H, Qamar MM, Zafar F, et al. COVID-19: Clinical laboratory diagnosis and monitoring of novel coronavirus infected patients using molecular, serological and biochemical markers: A review. *Int J Immunopathol Pharmacol*. 2022;**36**:3946320221115320. [PubMed ID: [35840546](#)]. [PubMed Central ID: [PMC9289644](#)]. <https://doi.org/10.1177/03946320221115316>.
5. Battaglini D, Lopes-Pacheco M, Castro-Faria-Neto HC, Pelosi P, Rocco PRM. Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19. *Front Immunol*. 2022;**13**:857573. [PubMed ID: [35572561](#)]. [PubMed Central ID: [PMC9091347](#)]. <https://doi.org/10.3389/fimmu.2022.857573>.

6. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med.* 2020;**26**(10):1636-43. [PubMed ID: 32839624]. [PubMed Central ID: PMC7869028]. <https://doi.org/10.1038/s41591-020-1051-9>.
7. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. *Clin Chem Lab Med.* 2020;**58**(7):1021-8. [PubMed ID: 32286245]. <https://doi.org/10.1515/cclm-2020-0369>.
8. Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. *JCI Insight.* 2021;**6**(1). [PubMed ID: 33232303]. [PubMed Central ID: PMC7821609]. <https://doi.org/10.1172/jci.insight.144455>.
9. Meng Z, Guo S, Zhou Y, Li M, Wang M, Ying B. Applications of laboratory findings in the prevention, diagnosis, treatment, and monitoring of COVID-19. *Signal Transduct Target Ther.* 2021;**6**(1):316. [PubMed ID: 34433805]. [PubMed Central ID: PMC8386162]. <https://doi.org/10.1038/s41392-021-00731-z>.
10. Stegeman I, Ochodo EA, Guleid F, Holtman GA, Yang B, Davenport C, et al. Routine laboratory testing to determine if a patient has COVID-19. *Cochrane Database Syst Rev.* 2020;**11**(11). CD013787. [PubMed ID: 33211319]. [PubMed Central ID: PMC8078159]. <https://doi.org/10.1002/14651858.CD013787>.
11. Bai G, Zare H. Hospital Cost Structure and the Implications on Cost Management During COVID-19. *J Gen Intern Med.* 2020;**35**(9):2807-9. [PubMed ID: 32607935]. [PubMed Central ID: PMC7326305]. <https://doi.org/10.1007/s11606-020-05996-8>.
12. Mirhashemi SH, Mostafavi H, Mollajafari F, Ahmad ZZ, Hashempour R. Direct medical cost and cost analysis of COVID-19 in Iran: A multicenter cross-sectional study. *Int J Crit Illn Inj Sci.* 2022;**12**(1):10-6. [PubMed ID: 35433401]. [PubMed Central ID: PMC9008290]. https://doi.org/10.4103/ijciis.ijciis_57_21.
13. Dymicka-Piekarska V, Dorf J, Milewska A, Lukaszuk M, Kosidlo JW, Kaminska J, et al. Neutrophil/Lymphocyte Ratio (NLR) and Lymphocyte/Monocyte Ratio (LMR) - Risk of Death Inflammatory Biomarkers in Patients with COVID-19. *J Inflamm Res.* 2023;**16**:2209-22. [PubMed ID: 37250103]. [PubMed Central ID: PMC10224725]. <https://doi.org/10.2147/IJR.S409871>.
14. Ertekin B, Yortanlı M, Ozelbaykal O, Dogru A, Girisgin AS, Acar T. The Relationship between Routine Blood Parameters and the Prognosis of COVID-19 Patients in the Emergency Department. *Emerg Med Int.* 2021;**2021**:7489675. [PubMed ID: 34868686]. [PubMed Central ID: PMC8633851]. <https://doi.org/10.1155/2021/7489675>.
15. Abensur Vuillaume L, Le Borgne P, Alame K, Lefebvre F, Berard L, Delmas N, et al. Neutrophil-to-Lymphocyte Ratio and Early Variation of NLR to Predict In-Hospital Mortality and Severity in ED Patients with SARS-CoV-2 Infection. *J Clin Med.* 2021;**10**(12). [PubMed ID: 34207918]. [PubMed Central ID: PMC8229672]. <https://doi.org/10.3390/jcm10122563>.
16. Regolo M, Vaccaro M, Sorce A, Stancanelli B, Colaci M, Natoli G, et al. Neutrophil-to-Lymphocyte Ratio (NLR) Is a Promising Predictor of Mortality and Admission to Intensive Care Unit of COVID-19 Patients. *J Clin Med.* 2022;**11**(8). [PubMed ID: 35456328]. [PubMed Central ID: PMC9027549]. <https://doi.org/10.3390/jcm11082235>.
17. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect.* 2020;**81**(1):e6-e12. [PubMed ID: 32283162]. [PubMed Central ID: PMC7195072]. <https://doi.org/10.1016/j.jinf.2020.04.002>.
18. Liu K, Tang S, Liu C, Ma J, Cao X, Yang X, et al. Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk. *Front Immunol.* 2024;**15**:1337241. [PubMed ID: 38481995]. [PubMed Central ID: PMC10933001]. <https://doi.org/10.3389/fimmu.2024.1337241>.
19. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol.* 2020;**146**(1):128-136 e4. [PubMed ID: 32425269]. [PubMed Central ID: PMC7233239]. <https://doi.org/10.1016/j.jaci.2020.05.008>.
20. Maddani SS, Gupta N, Umakanth S, Joylin S, Saravu K. Neutrophil-Lymphocyte Ratio in Patients with COVID-19 as a Simple Tool to Predict Requirement of Admission to a Critical Care Unit. *Indian J Crit Care Med.* 2021;**25**(5):535-9. [PubMed ID: 34177173]. [PubMed Central ID: PMC8196394]. <https://doi.org/10.5005/jip-journals-10071-23801>.
21. Chen L, Yu J, He W, Chen L, Yuan G, Dong F, et al. Risk factors for death in 1859 subjects with COVID-19. *Leukemia.* 2020;**34**(8):2173-83. [PubMed ID: 32546725]. [PubMed Central ID: PMC7296516]. <https://doi.org/10.1038/s41375-020-0911-0>.
22. Kosidlo JW, Wolszczak-Biedrzycka B, Matowicka-Karna J, Dymicka-Piekarska V, Dorf J. Clinical Significance and Diagnostic Utility of NLR, LMR, PLR and SII in the Course of COVID-19: A Literature Review. *J Inflamm Res.* 2023;**16**:539-62. [PubMed ID: 36818192]. [PubMed Central ID: PMC9930576]. <https://doi.org/10.2147/IJR.S395331>.
23. Fois SS, Zinellu E, Zinellu A, Merella M, Pau MC, Carru C, et al. Comparison of Clinical Features, Complete Blood Count Parameters, and Outcomes between Two Distinct Waves of COVID-19: A Monocentric Report from Italy. *Healthcare (Basel).* 2022;**10**(12). [PubMed ID: 36553950]. [PubMed Central ID: PMC9778399]. <https://doi.org/10.3390/healthcare10122427>.
24. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. *Int Immunopharmacol.* 2020;**84**:106504. [PubMed ID: 32304994]. [PubMed Central ID: PMC7152924]. <https://doi.org/10.1016/j.intimp.2020.106504>.
25. Eissa M, Shaarawy S, Abdellateif MS. The Role of Different Inflammatory Indices in the Diagnosis of COVID-19. *Int J Gen Med.* 2021;**14**:7843-53. [PubMed ID: 34795505]. [PubMed Central ID: PMC8593597]. <https://doi.org/10.2147/IJGM.S337488>.
26. Ayalew G, Mulugeta B, Haimanot Y, Adane T, Bayleyegn B, Abere A. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Can Predict the Severity in COVID-19 Patients from Ethiopia: A Retrospective Study. *Int J Gen Med.* 2022;**15**:7701-8. [PubMed ID: 36238542]. [PubMed Central ID: PMC9553031]. <https://doi.org/10.2147/IJGM.S383558>.
27. Ortega-Rojas S, Salazar-Talla L, Romero-Cerdan A, Soto-Becerra P, Diaz-Velez C, Urrunaga-Pastor D, et al. The Neutrophil-to-Lymphocyte Ratio and the Platelet-to-Lymphocyte Ratio as Predictors of Mortality in Older Adults Hospitalized with COVID-19 in Peru. *Dis Markers.* 2022;**2022**:2497202. [PubMed ID: 35937941]. [PubMed Central ID: PMC9346540]. <https://doi.org/10.1155/2022/2497202>.
28. Haryati H, Wicaksono B, Syahadatina M. Complete blood count derived inflammation indexes predict outcome in COVID-19 patients: a study in Indonesia. *J Infect Dev Ctries.* 2023;**17**(3):319-26. [PubMed ID: 37023436]. <https://doi.org/10.3855/jidc.16527>.
29. Cho JK, Kim MW, Choi IS, Moon UY, Kim MJ, Sohn I, et al. Optimal cutoff of pretreatment neutrophil-to-lymphocyte ratio in head and neck cancer patients: a meta-analysis and validation study. *BMC*

- Cancer*. 2018;**18**(1):969. [PubMed ID: [30309318](#)]. [PubMed Central ID: [PMC6182814](#)]. <https://doi.org/10.1186/s12885-018-4876-6>.
30. Diaz-Couselo FA, Flagel S, Nicolini C, Halac S, Manzano N, Aguirre M, et al. Impact of high neutrophil-to-lymphocyte ratio on survival in hospitalized cancer patients with COVID-19. *Cancer Med*. 2023;**12**(6):7164-9. [PubMed ID: [36372937](#)]. [PubMed Central ID: [PMC9877941](#)]. <https://doi.org/10.1002/cam4.5426>.
 31. Vano YA, Oudard S, By MA, Tetu P, Thibault C, Aboudagga H, et al. Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. *PLoS One*. 2018;**13**(4). e0195042. [PubMed ID: [29624591](#)]. [PubMed Central ID: [PMC5889159](#)]. <https://doi.org/10.1371/journal.pone.0195042>.
 32. Shen QQ, Gao J, Tao H, Wang ST, Wang FJ, Chen YY, et al. The derived neutrophil-lymphocyte ratio and the neutrophil-lymphocyte ratio are related to poor prognosis in Hodgkin lymphoma patients. *Am J Blood Res*. 2021;**11**(1):100-10. [PubMed ID: [33796397](#)]. [PubMed Central ID: [PMC8010605](#)].
 33. Sharma D, Spring KJ, Bhaskar SM. Role of Neutrophil-Lymphocyte Ratio in the Prognosis of Acute Ischaemic Stroke After Reperfusion Therapy: A Systematic Review and Meta-analysis. *Journal of Central Nervous System Disease*. 2022;**14**. <https://doi.org/10.1177/11795735221092518>.
 34. Lu Z, Chen X, Ge H, Li M, Feng B, Wang D, et al. Neutrophil-Lymphocyte Ratio in Patients with Hypertriglyceridemic Pancreatitis Predicts Persistent Organ Failure. *Gastroenterol Res Pract*. 2022;**2022**:8333794. [PubMed ID: [35340692](#)]. [PubMed Central ID: [PMC8942680](#)]. <https://doi.org/10.1155/2022/8333794>.
 35. Yao W, Wang W, Tang W, Lv Q, Ding W. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune inflammation index (SII) to predict postoperative pneumonia in elderly hip fracture patients. *J Orthop Surg Res*. 2023;**18**(1):673. [PubMed ID: [37697317](#)]. [PubMed Central ID: [PMC10496383](#)]. <https://doi.org/10.1186/s13018-023-04157-x>.
 36. Ninla-Aesong P, Kietdumrongwong P, Neupane SP, Puangsri P, Jongkrijak H, Chotipong P, et al. Relative value of novel systemic immune-inflammatory indices and classical hematological parameters in predicting depression, suicide attempts and treatment response. *Sci Rep*. 2024;**14**(1):19018. [PubMed ID: [39152198](#)]. [PubMed Central ID: [PMC11329510](#)]. <https://doi.org/10.1038/s41598-024-70097-z>.
 37. Li J, Wang X, Jia W, Wang K, Wang W, Diao W, et al. Association of the systemic immuno-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with diabetic microvascular complications. *Front Endocrinol (Lausanne)*. 2024;**15**:1367376. [PubMed ID: [38660516](#)]. [PubMed Central ID: [PMC11039910](#)]. <https://doi.org/10.3389/fendo.2024.1367376>.
 38. Serban D, Stoica PL, Dascalu AM, Bratu DG, Cristea BM, Alius C, et al. The Significance of Preoperative Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Systemic Inflammatory Index (SII) in Predicting Severity and Adverse Outcomes in Acute Calculous Cholecystitis. *J Clin Med*. 2023;**12**(21). [PubMed ID: [37959411](#)]. [PubMed Central ID: [PMC10648653](#)]. <https://doi.org/10.3390/jcm12216946>.